Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Pannuti

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
European Journal of Cancer & Clinical Oncology|November 1, 1986
Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic studyF Pannuti, C M Camaggi, E Strocchi, et al.
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|August 1, 1984
Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancerF Pannuti, A Martoni, E Piana, et al.
Oncology|January 1, 1990
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancerA Martoni, E Piana, M Guaraldi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 1995
CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative studyA Martoni, C Zamagni, B Bellanova, et al.
Oncology|January 1, 1981
Experimental study on the anabolic and androgenic/antiandrogenic activity of different dose levels of medroxyprogesterone acetate (MAP) in ratsF Pannuti, R Gaggi, G Murari-Colalongo, et al.
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|October 1, 1984
The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patientsG Lelli, B Angelelli, L Zanichelli, et al.
Investigational New Drugs|January 1, 1985
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancerP Periti, G R della Cuna, F Pannuti, et al.
Journal of Chemotherapy (Florence, Italy)|August 1, 1989
Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot studyG Lelli, A Tononi, P Bacchetti, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patientsC M Camaggi, E Strocchi, M Giovannini, et al.
Anticancer Research|August 26, 1998
Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesisA Martoni, E Piana, E Strocchi, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
European Journal of Cancer & Clinical Oncology|November 1, 1986
Intrahepatic arterial administration of 4'epidoxorubicin (epirubicin) in advanced cancer patients. A pharmacokinetic studyF Pannuti, C M Camaggi, E Strocchi, et al.
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|August 1, 1984
Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancerF Pannuti, A Martoni, E Piana, et al.
Oncology|January 1, 1990
Comparative phase II study of idarubicin versus doxorubicin in advanced breast cancerA Martoni, E Piana, M Guaraldi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 1, 1995
CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative studyA Martoni, C Zamagni, B Bellanova, et al.
Oncology|January 1, 1981
Experimental study on the anabolic and androgenic/antiandrogenic activity of different dose levels of medroxyprogesterone acetate (MAP) in ratsF Pannuti, R Gaggi, G Murari-Colalongo, et al.
Chemioterapia : International Journal of the Mediterranean Society of Chemotherapy|October 1, 1984
The effect of high dose medroxyprogesterone acetate on water and salt metabolism in advanced cancer patientsG Lelli, B Angelelli, L Zanichelli, et al.
Investigational New Drugs|January 1, 1985
First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancerP Periti, G R della Cuna, F Pannuti, et al.
Journal of Chemotherapy (Florence, Italy)|August 1, 1989
Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot studyG Lelli, A Tononi, P Bacchetti, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1983
Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patientsC M Camaggi, E Strocchi, M Giovannini, et al.
Anticancer Research|August 26, 1998
Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cis-platinum-induced emesisA Martoni, E Piana, E Strocchi, et al.
Pageof 10